Teva Pharmaceutical Industries Investor Presentation — February 2019

Document content

Teva Pharmaceutical Industries Ltd.

Fourth Quarter 2018 Results

February 13, 2019Cautionary Note Regarding Forward -Looking Statements

This presentation contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , which are based on management ’s current beliefs and expectations and are subject to

substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements todiffer significantly from that expressed or implied by such forward -looking statements.

Important factors that could cause or contribute to such differences include risks relating to :

•our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic product s; competition for our specialty products, especially COPAXONE®, our leading medicine, which

faces competition from existing and potential additional generic versions and orally -administered alternatives; the uncertainty of commercial success of AJOVY®or AUSTEDO®; competition from companies with greater

resources and capabilities; efforts of pharmaceutical companies to limit the use of generics, including through legislation a nd regulations; consolidation of our customer base and commercial alliances among our

customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; price erosion relating to our products, both from

competing products and increased regulation; delays in launches of new products and our ability to achieve expected results f rominvestments in our product pipeline; our ability to take advantage of high -value

opportunities; the difficulty and expense of obtaining licenses to proprietary technologies; and the effectiveness of our pat ents and other measures to protect our intellectual property rights ;

•our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions ormake new investments, may result in a further downgrade of our credit ratings; and our

inability to raise debt or borrow funds in amounts or on terms that are favorable to us ;

•our business and operations in general, including: failure to effectively execute our restructuring plan announced in Decembe r 2017 ; uncertainties related to, and failure to achieve, the potential benefits and success of our

new senior management team and organizational structure; harm to our pipeline of future products due to the ongoing review of our R&D programs; our ability to develop and commercialize additional pharmaceutical

products; potential additional adverse consequences following our resolution with the U.S. government of our FCPA investigati on;compliance with sanctions and other trade control laws; manufacturing or quality control